Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial

Panagiotis A. Konstantinopoulos, William T. Barry, Michael Birrer, Shannon N. Westin, Karen A. Cadoo, Geoffrey I. Shapiro, Erica L. Mayer, Roisin E. O'Cearbhaill, Robert L. Coleman, Bose Kochupurakkal, Christin Whalen, Jennifer Curtis, Sarah Farooq, Weixiu Luo, Julia Eismann, Mary K. Buss, Carol Aghajanian, Gordon B. Mills, Sangeetha Palakurthi, Paul KirschmeierJoyce Liu, Lewis C. Cantley, Scott H. Kaufmann, Elizabeth M. Swisher, Alan D. D'Andrea, Eric Winer, Gerburg M. Wulf, Ursula A. Matulonis

    Research output: Contribution to journalArticlepeer-review

    50 Scopus citations

    Fingerprint Dive into the research topics of 'Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial'. Together they form a unique fingerprint.

    Medicine & Life Sciences